JPMorgan Chase & Co. Trims Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
JPMorgan Chase & Co. lessened its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 5.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 19,745 shares of the company’s stock after selling 1,062 shares during the quarter. JPMorgan Chase & Co.’s holdings in Enliven Therapeutics were worth $444,000 as of […]
JPMorgan Chase & Co. lessened its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 5.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 19,745 shares of the company’s stock after selling 1,062 shares during the quarter. JPMorgan Chase & Co.’s holdings in Enliven Therapeutics were worth $444,000 as of […]
